Skip to main content

Table 2 Baseline characteristics of patients who received thrombolytic treatment by outcome groups

From: Interleukin-10 facilitates the selection of patients for systemic thrombolysis

  Poor outcome (n = 81) Good outcome (n = 103) p
Age, years 71.4 ± 9.3 64.3 ± 13.5 <0.0001
Male gender, % 54.3 61.2 0.370
Time from stroke onset, minutes 84.7 ± 36.4 102.9 ± 83.8 0.234
TOAST    0.095
 - Atherothrombotic, n (%) 16.0 13.6  
 - Cardioembolic, n (%) 59.3 49.5  
 - Lacunar, n (%) 0 5.8  
 - Undetermined, n (%) 24.7 31.1  
History of hypertension, n (%) 59.3 50.5 0.297
History of diabetes, n (%) 12.3 9.7 0.637
History of dyslipemia, n (%) 21.0 32.0 0.099
Smoking history, n (%) 14.8 12.6 0.672
Alcohol consumption, n (%) 6.2 9.7 0.429
History of coronary disease, n (%) 11.1 12.6 0.822
History of atrial fibrillation, n (%) 35.8 25.2 0.145
Previous stroke or TIA, n (%) 14.8 8.7 0.245
Systolic blood pressure, mmHg 159.1 ± 24.4 155.6 ± 27.6 0.327
Diastolic blood pressure, mmHg 86.7 ± 16.5 83.5 ± 15.1 0.180
Body temperature, °C 36.2 ± 2.3 36.4 ± 0.4 0.218
Glucose levels, mg/dL 129.5 ± 32.2 126.3 ± 40.0 0.142
Leukocytes, 103/mL 8.2 ± 2.3 8.7 ± 2.9 0.349
Platelets, 103/mL 223.6 ± 64.0 247.3 ± 86.7 0.086
Fibrinogen, mg/dL 433.7 ± 114.7 412.6 ± 138.3 0.069
NIHSS at admission 18 [14, 20] 11 [7, 16] <0.0001
DWI volume at admission, mL 56.0 ± 60.2 16.7 ± 20.2 <0.0001
MTT volume at admission, mL 143.2 ± 87.4 72.3 ± 79.9 <0.0001
Neuron-specific enolase (ng/mL) 23.8 ± 7.4 22.4 ± 7.2 0.202
Interleukin-10 (pg/mL) 12.9 ± 10.7 25.1 ± 17.9 <0.0001
Tumor necrosis factor-α (pg/mL) 13.8 ± 8.7 16.7 ± 11.5 0.057
Interleukin-6 (pg/mL) 21.1 ± 17.3 14.8 ± 9.9 0.002
Active metalloproteinase-9 (ng/mL) 27.8 ± 17.7 22.6 ± 12.1 0.026
Glutamate (μM) 212.7 ± 147.5 171.4 ± 152.6 0.065